Getagraph.com logo
NASDAQ Composite: ( -0.27%) 16 749
S&P 500
(-0.12%) 5 301.57 points
Dow Jones
(-0.06%) 39 781 points
Nasdaq
(-0.27%) 16 749 points
Oil
(-1.25%) $78.80
Gas
(-2.11%) $2.69
Gold
(-0.15%) $2 434.80
Silver
(-1.19%) $32.04
Platinum
(0.01%) $1 063.80
USD/EUR
(0.08%) $0.921
USD/NOK
(-0.36%) $10.66
USD/GBP
(-0.01%) $0.787
USD/RUB
(-0.67%) $90.07

Realaus laiko atnaujinimai Ocugen Inc [OCGN]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
BUY
100.00%
return 9.47%
SELL
100.00%
return -10.94%
Atnaujinta21 geg. 2024 @ 16:35
25% discount on Stockinvest.us - Use code: Podcast

-5.72% $ 1.810

PIRKIMAS 139265 min ago

@ $0.657

Išleistas: 14 vas. 2024 @ 22:30

Grąža: 175.73%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 6.16 %

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 16:35):
Profile picture for Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...

Stats
Šios dienos apimtis 1.08M
Vidutinė apimtis 9.47M
Rinkos kapitalizacija 465.82M
EPS $0 ( 2024-05-14 )
Kita pelno data ( $-0.0600 ) 2024-08-19
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -7.87
ATR14 $0.00800 (0.45%)
Insider Trading
Date Person Action Amount type
2024-04-16 Qamar Huma Buy 308 465 Option (Right to Buy)
2024-03-18 Qamar Huma Sell 0 Common Stock
2023-09-15 Breininger Michael Buy 0
2024-01-03 Musunuri Shankar Sell 180 204 Common Stock
2024-01-03 Upadhyay Arun Sell 41 633 Common Stock
INSIDER POWER
65.74
Last 96 transactions
Buy: 10 862 012 | Sell: 2 992 475

Tūris Koreliacija

Ilgas: -0.53 (weak negative)
Trumpas: -0.14 (neutral)
Signal:(23.998) Neutral

Ocugen Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
QNST0.939
PVAL0.937
LFMDP0.935
RNA0.935
GRID0.933
DWLD0.932
AVO0.93
SG0.928
QFIN0.927
SHLD0.926
10 Labiausiai neigiamai susiję koreliacijos
UONEK-0.918
RMGC-0.904
PRTS-0.902
TTEC-0.902
ACAD-0.9
UONE-0.897
AGRX-0.895
EEIQ-0.895
NLSP-0.893
QNRX-0.892

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ocugen Inc Koreliacija - Valiuta/Žaliavos

The country flag -0.48
( neutral )
The country flag -0.01
( neutral )
The country flag 0.00
( neutral )
The country flag -0.39
( neutral )
The country flag 0.03
( neutral )
The country flag 0.12
( neutral )

Ocugen Inc Finansinės ataskaitos

Annual 2023
Pajamos: $6.04M
Bruto pelnas: $5.33M (88.34 %)
EPS: $-0.260
FY 2023
Pajamos: $6.04M
Bruto pelnas: $5.33M (88.34 %)
EPS: $-0.260
FY 2022
Pajamos: $0
Bruto pelnas: $-1.07M (0.00 %)
EPS: $-0.360
FY 2021
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-0.300

Financial Reports:

No articles found.

Ocugen Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.